Taysha Gene Therapies, Inc. (TSHA)
NASDAQ$1.72
Market Cap
$352.6M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
88 of 924
Rank in Industry
65 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
TSHA Insider Trading Activity
TSHA Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $2,999,999 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| Manning Paul B | 10 percent owner | 1 | $3M | 0 | $0 | $3M |
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, …
Insider Activity of Taysha Gene Therapies, Inc.
Over the last 12 months, insiders at Taysha Gene Therapies, Inc. have bought $3M and sold $0 worth of Taysha Gene Therapies, Inc. stock.
On average, over the past 5 years, insiders at Taysha Gene Therapies, Inc. have bought $6.24M and sold $975,279 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Manning Paul B (10 percent owner) — $3M.
The last purchase of 1,333,333 shares for transaction amount of $3M was made by Manning Paul B (10 percent owner) on 2024‑06‑27.
List of Insider Buy and Sell Transactions, Taysha Gene Therapies, Inc.
| 2024-06-27 | Manning Paul B | 10 percent owner | 1.33M 0.7863% | $2.25 | $3M | -6.45% | ||
| 2023-11-17 | Manning Paul B | 10 percent owner | 100,000 0.0519% | $1.63 | $163,000 | +27.65% | ||
| 2023-08-24 | Sale | Alam Kamran | Chief Financial Officer | 33,000 0.0537% | $2.33 | $76,890 | -1.71% | |
| 2023-08-16 | Manning Paul B | 10 percent owner | 16.47M 11.9647% | $0.90 | $14.82M | +19.17% | ||
| 2023-08-16 | Nolan Sean P. | Chief Executive Officer | 444,444 0.3229% | $0.90 | $400,000 | +19.17% | ||
| 2023-08-16 | Stalfort John A III | director | 777,778 0.5651% | $0.90 | $700,000 | +19.17% | ||
| 2023-08-16 | Donenberg Phillip B. | director | 111,111 0.0807% | $0.90 | $100,000 | +19.17% | ||
| 2023-07-13 | Sale | Session R.A. II | 10 percent owner | 5,344 0.0084% | $0.70 | $3,741 | +224.29% | |
| 2023-07-12 | Sale | Session R.A. II | 10 percent owner | 80,528 0.1263% | $0.71 | $57,030 | +218.06% | |
| 2023-06-23 | Sale | Session R.A. II | 10 percent owner | 18,100 0.0305% | $0.70 | $12,735 | +242.42% | |
| 2023-06-22 | Sale | Session R.A. II | 10 percent owner | 10,508 0.0163% | $0.70 | $7,384 | +215.86% | |
| 2023-06-21 | Sale | Session R.A. II | 10 percent owner | 138,962 0.2204% | $0.70 | $97,635 | +222.10% | |
| 2023-06-20 | Sale | Session R.A. II | 10 percent owner | 295,653 0.4778% | $0.71 | $210,209 | +223.55% | |
| 2023-05-16 | Nagendran Sukumar | President and Head of R&D | 5,000 0.0078% | $0.68 | $3,400 | +172.40% | ||
| 2022-10-31 | Manning Paul B | director | 1.5M 3.9684% | $2.00 | $3M | -35.47% | ||
| 2022-08-23 | Sale | Alam Kamran | Chief Financial Officer | 3,325 0.0081% | $3.47 | $11,538 | -68.01% | |
| 2022-08-18 | Sale | Alam Kamran | Chief Financial Officer | 11,482 0.0271% | $3.75 | $43,058 | -71.39% | |
| 2022-07-05 | Sale | PRASAD SUYASH | CMO and Head of R&D | 3,905 0.0095% | $3.51 | $13,707 | -48.86% | |
| 2022-06-29 | Sale | PRASAD SUYASH | CMO and Head of R&D | 12,324 0.0304% | $3.81 | $46,954 | -51.95% | |
| 2022-02-03 | Manning Paul B | 76,602 0.2022% | $7.84 | $600,560 | -59.00% |
Total: 34
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Manning Paul B | 10 percent owner | 1333333 0.6504% | $2.29M | 9 | 0 | <0.0001% |
| Session R.A. II | 10 percent owner | 8871747 4.3276% | $15.26M | 1 | 6 | <0.0001% |
| Nolan Sean P. | Chief Executive Officer | 1535545 0.749% | $2.64M | 2 | 0 | <0.0001% |
| Stalfort John A III | director | 999381 0.4875% | $1.72M | 1 | 0 | +19.17% |
| Donenberg Phillip B. | director | 114111 0.0557% | $196,270.92 | 2 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$5,911,307 | 70 | -1.38% | $309.77M | |
$109,415,500 | 33 | 18.13% | $353.41M | |
$41,446,394 | 27 | 12.91% | $340.18M | |
$14,865,077 | 18 | -28.56% | $389.16M | |
$49,750,490 | 17 | 37.19% | $307.1M |
TSHA Institutional Investors: Active Positions
| Increased Positions | 74 | +67.27% | 37M | +23.42% |
| Decreased Positions | 41 | -37.27% | 25M | -16.07% |
| New Positions | 29 | New | 10M | New |
| Sold Out Positions | 16 | Sold Out | 4M | Sold Out |
| Total Postitions | 143 | +30% | 168M | +7.36% |
TSHA Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Avoro Capital Advisors Llc | $32,000.00 | 9.76% | 20M | +1M | +7.24% | 2024-12-31 |
| Morgan Stanley | $28,225.00 | 8.61% | 17.64M | +10M | +130.17% | 2024-12-31 |
| Fmr Llc | $26,185.00 | 7.98% | 16.37M | -2M | -12.38% | 2024-12-31 |
| Blackrock, Inc. | $21,650.00 | 6.6% | 13.53M | +10,934 | +0.08% | 2024-12-31 |
| Ra Capital Management, L.P. | $17,396.00 | 5.3% | 10.87M | 0 | 0% | 2024-12-31 |
| Octagon Capital Advisors Lp | $16,720.00 | 5.1% | 10.45M | +6M | +128.55% | 2024-12-31 |
| Vanguard Group Inc | $14,251.00 | 4.35% | 8.91M | +641,305 | +7.76% | 2024-12-31 |
| Rtw Investments, Lp | $13,876.00 | 4.23% | 8.67M | -6M | -41.98% | 2024-12-31 |
| Siren, L.L.C. | $10,564.00 | 3.22% | 6.6M | +2M | +35.3% | 2024-12-31 |
| State Street Corp | $10,359.00 | 3.16% | 6.47M | +3M | +86.63% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.